Cellectar Announces Late-Breaking Poster Presentations at AACR 2018 Featuring PDCs and CLR 131

Mar 15, 2018

Phase 1 Clinical Data Demonstrating CLR 124 Uptake in Brain Tumors Accepted for Oral Presentation at the 12th World Congress of the World Federation of Nuclear Medicine and Biology

Mar 6, 2018

Cellectar Biosciences to Present at Upcoming March Conferences

Mar 5, 2018

Cellectar Biosciences to Present at the 2018 BIO CEO & Investor Conference

Feb 8, 2018

Cellectar Receives USPTO Notice of Allowance for Patent Covering Use of CLR 131 in Multiple Myeloma

Feb 7, 2018

Cellectar Initiates DLBCL Cohort in Phase 2 Trial of CLR 131 in Refractory B-Cell Hematologic Cancers

Jan 29, 2018

Cellectar Biosciences to Participate at Noble Capital Markets’ Fourteenth Annual Investor Conference

Jan 22, 2018

Cellectar Biosciences to Participate at Biotech Showcase 2018

Jan 4, 2018

Cellectar Files IND for Phase 1 Trial of CLR 131 in Pediatric Cancers

Dec 14, 2017

Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort in Phase 2 Trial of CLR 131

Dec 6, 2017